Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
37.8M
-
Number of holders
-
110
-
Total 13F shares, excl. options
-
30.2M
-
Shares change
-
-404K
-
Total reported value, excl. options
-
$275M
-
Value change
-
-$4.48M
-
Put/Call ratio
-
0.28
-
Number of buys
-
45
-
Number of sells
-
-52
-
Price
-
$9.04
Significant Holders of Entrada Therapeutics, Inc. - COMMON STOCK (TRDA) as of Q1 2025
123 filings reported holding TRDA - Entrada Therapeutics, Inc. - COMMON STOCK as of Q1 2025.
Entrada Therapeutics, Inc. - COMMON STOCK (TRDA) has 110 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 30.2M shares
of 37.8M outstanding shares and own 80.1% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (4.87M shares), 5AM Venture Management, LLC (4.41M shares), MPM ASSET MANAGEMENT LLC (4.38M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.74M shares), JANUS HENDERSON GROUP PLC (2.12M shares), BlackRock, Inc. (1.99M shares), VANGUARD GROUP INC (1.58M shares), FMR LLC (1.24M shares), WELLINGTON MANAGEMENT GROUP LLP (1.05M shares), and StepStone Group LP (761K shares).
This table shows the top 110 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.